Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd has announced promising advancements in developing a blood test for gastric cancer, identifying combinations of protein biomarkers that can distinguish between cancer patients and healthy individuals with high accuracy. This non-invasive diagnostic method, showing over 75% sensitivity and 90% specificity, could offer a simpler and potentially life-saving alternative to current invasive detection methods. The company plans to further validate these findings and develop a commercial blood test aimed at early, more treatable stages of the disease.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.